Suzhou Pharmaserve Technology Co., Ltd.

Indication

The injectable generic formulation of cetrorelix Pharmaserve is used in assisted reproduction to inhibit premature luteinizing hormone surges. In addition, cetrorelix has indications in hormone-sensitive cancers of the prostate and breast and certain benign gynaecological disorders such as endometriosis, uterine fibroids and endometrial thinnin

Mode of Action:

Cetrorelix Pharmaserve binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Pharmacodynamics:

Cetrorelix Pharmaserve is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner.

Metabolism:

In in vitro studies, cetrorelix Pharmaserve was stable against phase I- and phase II-metabolism. Cetrorelix was transformed by peptidases, and the (1-4) peptide was the predominant metabolite.

Absorption

In in vitro studies, cetrorelix Pharmaserve was stable against phase I- and phase II-metabolism. Cetrorelix was transformed by peptidases, and the (1-4) peptide was the predominant metabolite.

Mechanism of Action

Cetrorelix Pharmaserve blocks the effects of Gonadotropin Releasing Hormone (GnRH) and regulates the amount of luteinizing hormone (LH) released that triggers ovulation during the menstrual cycle. Some hormone therapies result in premature ovulation which causes eggs to be released before they are capable of being fertili

Pharmaserve’s Technology of SynthesisCetrorelix Acetate API Solid phase reactor is required in the production of Cetrorelix Acetate API. Pharmaserve adopts a new type of special solid phase reactor for Cetrorelix Acetate, including reactor shell, air inlet pipe, air outlet pipe, gas distribution component and solid phase catalytic component. In the production process of Semaglutide product itself, the equipment of the invention is suitable for solid phase catalytic reaction, which improves the reaction effect, shortens the reaction time, and is suitable for the production of Cetrorelix Acetate, making the final product more pure.We respect our customer's requirements of strict regulatory compliance and specification needs by offering the API - Active Pharmaceutical Ingredients and intermediates transparently while offering easy access to manufacturer / supplier / principals with affordable and high-quality raw materials. If you are looking for the API -Active Pharmaceutical Ingredients Cetrorelix acetate, 120287-85-6 manufacturer supplier who is reliable and meets your required quality standard requirements in the first place, you are at the right place!

When the device of the invention is used to produce Cetrorelix Acetate API, the overall reaction time is reduced by 20% ‑ 30%; At the same time, the production cost of the whole process is reduced, making the cost reduced by about 10%, which is suitable for promotion and use, and promoting the further research and development of Cetrorelix Acetate.

Purification of Pharmaserve Cetrorelix Acetate API       

 There are many impurities in the crude product of solid phase synthesis of Cetrorelix Acetate that affect the purity and yield of the sample. At present, there are many studies on the purification of Cetrorelix Acetate, and the purity can reach more than 99%. However, the solubility of the finished product obtained by the existing purification methods is not good, and other means are needed to improve the solubility of the finished product in the subsequent research and application process. Pharmaserve uses the latest peptide purification technology. The purity of the finished product reaches 99%, and the single impurity is less than 0.2%. At the same time, the solubility of the finished product is good, and the sample recovery rate can reach 100%. This process is stable and controllable, suitable for industrial production, and it can effectively reduce your scientific research or industrial needs.